2-(2-tert-butoxy-2-oxoethoxy)benzoic acid | 647851-06-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2-tert-butoxy-2-oxoethoxy)benzoic acid
• 英文别名: 2-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethoxy]benzoic acid
• CAS: 647851-06-7
• 化学式: C₁₃H₁₆O₅
• 分子量: 252.267
• InChiKey: CLZZAEZVJOKUNM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  benzyl 2-(2-tert-butoxy-2-oxoethoxy)benzoate 在 钯 氢气 、 四氢呋喃 作用下， 以 四氢呋喃 为溶剂， 反应 22.0h， 以to afford 2-(2-tert-butoxy-2-oxoethoxy)benzoic acid (1.14 g, 99%) as a tan amorphous solid的产率得到2-(2-tert-butoxy-2-oxoethoxy)benzoic acid
  参考文献：
  名称：

  BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS

  摘要：

  本发明提供了基于硝基噻唑骨架的新型抗微生物化合物，能够对广泛的人类病原体表现出抗菌和抗寄生虫作用。这些新型化合物能够延长对革兰氏阳性菌的作用，包括对耐药菌MRSA的作用。在革兰氏阳性生物中，它们能够特异性地靶向和功能性地抑制微生物对表面的附着和生物膜形成。在革兰氏阴性细菌中，包括肠毒性E. coli菌株，这些化合物通过抑制毛细管亚单位的组装成为粘附纤维，发挥作为毛细管抑制剂的作用。其中几种化合物对革兰氏阳性菌表现出强效的抗微生物活性，可能涉及新的靶点。许多苯并噻吩衍生物在低微克/毫升范围内表现出抗微生物活性，并在纳摩尔范围内阻止生物膜形成；这些范围被认为是治疗上实用的范围。

  公开号：

  US20120010187A1

文献信息

• [EN] COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE ACTIVITY AND USE THEREOF<br/>[FR] COMPOSÉS POUR L'INHIBITION DE L'ACTIVITÉ DE L'INDOLÉAMINE 2,3-DIOXYGÉNASE ET LEUR UTILISATION
  申请人：ENSEMBLE THERAPEUTICS CORP

  公开号：WO2018102006A1

  公开（公告）日：2018-06-07

  The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of indoleamine-2,3-dioxygenase (IDO) activity, and methods of treating IDO-related disorders.

  这项发明涉及化合物及其药用可接受的组合物，用作吲哌酮胺-2,3-二氧化酶（IDO）活性的拮抗剂，并用于治疗与IDO相关的疾病的方法。
• Compositions and methods for treating tuberculosis
  申请人：Hoffman Paul S.

  公开号：US09333193B2

  公开（公告）日：2016-05-10

  The invention provides for the use of antimicrobial chemical entities based on a nitrothiazolide backbone that exhibit anti-mycobacteria activity, including the mycobacterium causing tuberculosis. Multiple compounds were synthesized and screened for anti-tuberculosis activity. Disclosed herein are a series of compounds with anti-tuberculosis activity, including six leads that completely inhibited bacterial growth at 5 micrograms per ml or less. Three of these compounds were tested to determine MIC and these ranged between 1 and 4 micrograms per ml against both drug susceptible Mycobacterium tuberculosis strains and strains that are multi-drug resistant (MDR) including XDR strains. The compounds developed are derived from parent compound nitazoxanide, which had no inhibitory activity in the stringent testing format used herein. The derivatives were synthesized using a di-nitro-thiophene or 4-Chloro-5-Nitro-thiazole scaffold and R groups connected via a peptide bond (NHCO) to cyclic compounds such as benzene, thiophene or furans. Many of these compounds have broad spectrum activity against Gram positive bacteria including Staphylococcus aureus (MRSA) and Staphylococcus epidermidis. Several of these lead compounds were not toxic for mice at 200 mg/Kg doses administered over a period of three days.

  该发明提供了基于硝基噻唑酮骨架的抗微生物化学实体的使用，这些实体表现出抗分枝杆菌活性，包括导致结核病的分枝杆菌。合成了多种化合物，并对其进行了抗结核活性筛选。本文披露了一系列具有抗结核活性的化合物，包括六种在每毫升5微克或更低浓度下完全抑制细菌生长的前导化合物。其中三种化合物经过测试，确定了最小抑菌浓度（MIC），在药物敏感的结核分枝杆菌菌株和多药耐药（MDR）株，包括XDR株中，MIC值在1至4微克/毫升之间。开发的化合物源自母体化合物硝唑咪唑，该化合物在本文使用的严格测试格式中没有抑制活性。这些衍生物是使用二硝基噻吩或4-氯-5-硝基噻唑骨架合成的，并且通过肽键（NHCO）连接到苯、噻吩或呋喃等环状化合物的R基团。这些化合物中的许多具有广谱活性，可对抗革兰氏阳性细菌，包括金黄色葡萄球菌（MRSA）和表皮葡萄球菌。其中几种前导化合物在连续三天内以每公斤200毫克的剂量对小鼠不具有毒性。
• [EN] COMPOUNDS AND THERAPEUTIC USES THEREOF<br/>[FR] COMPOSÉS ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：CENTAURI THERAPEUTICS LTD

  公开号：WO2017060729A1

  公开（公告）日：2017-04-13

  The invention relates to novel compounds with the ability to link an immune response to a defined therapeutic target, to the use of said compounds in treating cancer and a disease or disorder mediated and/or caused by an infective agent, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process.

  该发明涉及具有将免疫反应与特定治疗靶标联系起来的新化合物，以及将该类化合物用于治疗癌症、由感染性因子介导和/或引起的疾病或紊乱，包含该类化合物的组合物，其制备过程以及用于该过程的新中间体。
• COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS
  申请人：Hoffman Paul S.

  公开号：US20130317070A1

  公开（公告）日：2013-11-28

  The invention provides for the use of antimicrobial chemical entities based on a nitrothiazolide backbone that exhibit anti-mycobacteria activity, including the mycobacterium causing tuberculosis. Multiple compounds were synthesized and screened for anti-tuberculosis activity. Disclosed herein are a series of compounds with anti-tuberculosis activity, including six leads that completely inhibited bacterial growth at 5 micrograms per ml or less. Three of these compounds were tested to determine MIC and these ranged between 1 and 4 micrograms per ml against both drug susceptible Mycobacterium tuberculosis strains and strains that are multi-drug resistant (MDR) including XDR strains. The compounds developed are derived from parent compound nitazoxanide, which had no inhibitory activity in the stringent testing format used herein. The derivatives were synthesized using a di-nitro-thiophene or 4-Chloro-5-Nitro-thiazole scaffold and R groups connected via a peptide bond (NHCO) to cyclic compounds such as benzene, thiophene or furans. Many of these compounds have broad spectrum activity against Gram positive bacteria including Staphylococcus aureus (MRSA) and Staphylococcus epidermidis . Several of these lead compounds were not toxic for mice at 200 mg/Kg doses administered over a period of three days.

  本发明提供了基于硝基噻唑骨架的抗微生物化学实体的使用，其表现出抗分枝杆菌活性，包括导致结核病的分枝杆菌。多种化合物被合成并筛选以寻找抗结核病活性。本文披露了一系列具有抗结核病活性的化合物，包括六个引物，其在5微克/毫升或更低浓度下完全抑制了细菌生长。其中三种化合物被测试以确定MIC，这些化合物对药物敏感的结核分枝杆菌菌株和多重耐药（MDR）菌株（包括XDR菌株）的MIC范围在1至4微克/毫升之间。开发的化合物来源于父化合物硝唑酮，该化合物在本文所使用的严格测试格式中没有抑制活性。这些衍生物是使用二硝基噻吩或4-氯-5-硝基噻唑支架和连接到环化合物（如苯、噻吩或呋喃）的R基通过肽键（NHCO）合成的。其中许多化合物对革兰氏阳性细菌具有广谱活性，包括金黄色葡萄球菌（MRSA）和表皮葡萄球菌。其中几种引物化合物在3天内以200毫克/千克的剂量给小鼠注射时没有毒性。
• Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials
  申请人：Hoffman Paul S.

  公开号：US08835644B2

  公开（公告）日：2014-09-16

  The invention provides novel antimicrobial chemical entities based on a nitrothiazolide backbone that exhibit antibacterial and antiparasitic action against a wide range of human pathogens. The new classes of compounds show extended action against Gram positive bacteria including MRSA drug resistant pathogens. In the Gram-positive organisms, they specifically target and functionally inhibit microbial attachment to surfaces and biofilm formation. In Gram-negative bacteria, including enteroaggregative E. coli strains, these compounds function as pilicides by inhibiting the assembly of pilin subunits into adhesive filaments. Several of these compounds show potent antimicrobial action against Gram positive bacteria, perhaps involving novel targets. Many of the benzothiophene derivatives exhibit antimicrobial activity in the low micrograms per ml range and in blocking biofilm formation in the nanomolar range; ranges considered are well within the range of utility as therapeutics.

  本发明提供了基于硝基噻唑酮骨架的新型抗微生物化合物，对广泛的人类病原体表现出抗菌和抗寄生虫作用。这些新类化合物对革兰氏阳性细菌包括耐药性MRSA病原体具有延长作用。在革兰氏阳性生物中，它们特异性地靶向并功能性地抑制微生物附着于表面和生物膜形成。在革兰氏阴性细菌中，包括肠毒性E. coli菌株，这些化合物作为毛细管抑制剂，通过抑制毛细管亚单位的组装成为粘附丝。其中几种化合物对革兰氏阳性细菌表现出强效的抗微生物作用，可能涉及新的靶点。许多苯并噻吩衍生物在低微克/毫升范围内表现出抗微生物活性，并在纳摩尔范围内阻止生物膜形成;考虑到疗效范围，这些范围被认为是有用的治疗药物。